M. C. Riesco

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

C. Barbas, M. T. Agulló-Ortuño, J. López-Martín, 2018, Journal of cachexia, sarcopenia and muscle.

Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.

I. Arozarena, R. García-Carbonero, J. Capdevila, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

J. Tabernero, E. Polo, M. Valladares-Ayerbes, 2021, British Journal of Cancer.

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.

F. Al-Shahrour, G. Gómez-López, L. Álvarez-Vallina, 2019, European journal of cancer.

External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

M. Marazuela, A. Lamarca, J. Valle, 2021, Neuroendocrinology.

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

J. Vercher-Conejero, V. Pubul, A. García-Burillo, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects

M. Hidalgo, G. Capellá, R. Salazar, 2021, Journal for ImmunoTherapy of Cancer.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

E. Polo, M. Valladares-Ayerbes, F. Rivera, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.